NCardia and Pivot Park Screening Centre announced a collaboration to improve NCardia’s cardiovascular drug discovery service offerings and to expand Pivot Park Screening Centre’s knowledge about new and innovative assay technologies used to accelerate drug discoveries. Giving NCardia access to the Screening Centre’s ultra High Throughput Screening (uHTS) capability, this collaboration will serve NCardia’s mission which is to contribute to the efficiency of the drug discovery and development process by reducing the development length, costs and late stage attrition of novel drug candidates.

NCardia is a leading expert in human cardiovascular stem cell technology, disease modeling and cell-based assay products and services for cardiovascular drug discovery. NCardia developed a proprietary technology to differentiate fully functional human iPSC-derived cardiomyocytes exhibiting unique electrophysiological characteristics that make them exceptionally well-suited for disease modeling and phenotypic screening. Indeed, implemented in various contractility-, biochemistry- and electrophysiology-based assays, NCardia’s Pluricyte® Cardiomyocytes contribute to improve drug safety and efficacy screenings. Combining NCardia’s unique cardiovascular models and cardiovascular expertise with Pivot Park Screening Centre’s uHTS platform and extensive uHTS and assay development expertise will allow NCardia not only to dramatically improve the throughput of its drug efficacy screening using automation and miniaturization, but also to access a library of 300,000 high quality drug-like compounds to accelerate its developments and programs to advance cardiovascular research and development which will be available for cardiovascular drug discovery service projects.

Stefan Braam, CEO of NCardia, commented: “This collaboration expands NCardia’s offerings in a new direction as it will allow us to expand our service offerings with screening capabilities ranging from a few hundreds of compounds to millions of compounds. We believe that the combination of the high quality and unique characteristic of our cells with HTS will enable phenotypic screening at any throughput, thereby contributing to better more efficient drug discovery. We look forward to working with Pivot Park team!”

Helma Rutjes, COO of Pivot Park Screening Centre added: “Through this collaboration we are able to jointly accelerate the discovery of new medicines for a healthier society. By learning from each other and make use of each other’s expertise and facilities this will be a partnership of great value directly for both parties and indirectly for our future and current partners who are using our assay development and ultra High Throughput Screening facilities.”

More information about the Cardio.Flux Service can be found here.